ライフサイエンスコーパス: gastric tumor

1 and is associated with the ability to induce gastric tumor.

2 ed after laparoscopic wedge resection of the gastric tumor.

3 pretargeted molecular imaging and therapy in gastric tumors.

4 of Fzd7, blocks the initiation and growth of gastric tumors.

5 sequenced SMO and PTCH1 genes in a set of 39 gastric tumors.

6 riety of human cancers, including breast and gastric tumors.

7 gen (CEA/Tag) transgenic mice, which develop gastric tumors.

8 rin and p73 transcripts correlate in primary gastric tumors.

9 on is increased in several tumors especially gastric tumors.

10 cer cell lines, 61 colorectal tumors, and 87 gastric tumors.

11 Thirteen novel loci showed FSMs in >20% of gastric tumors.

12 ignificant risk factor in the development of gastric tumors.

13 r tyrosine kinase overexpressed in 18-20% of gastric tumors.

14 1 promoter hypermethylation in a total of 65 gastric tumors: 18 with frequent MSI (MSI-H), 8 with inf

15 ned E2F-4 mutations; these comprised 5 of 16 gastric tumors (31%), 4 of 12 ulcerative colitis-associa

16 However, how gastric tumors achieve WNT niche independence remains un

17 on, we applied an RNA-sequencing approach to gastric tumor and noncancerous specimens, generating 680

18 o directly track the delivery to the primary gastric tumor and to lung metastatic sites.

19 at fibrin is present in 64 to 75% of primary gastric tumors and 50 to 100% of metastatic gastric aden

20 or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse ty

21 o improve pertuzumab uptake in HER2-positive gastric tumors and allow the use of a pretargeted imagin

22 as determined by Western blot in 17 pairs of gastric tumors and corresponding non-neoplastic gastric

23 ngs overall survival in mice bearing NCI-N87 gastric tumors and HER2-positive patient-derived xenogra

24 valuated NPM1 gene and protein expression in gastric tumors and in corresponding non-neoplastic gastr

25 rase chain reaction (RT-qPCR) in 22 pairs of gastric tumors and in matched non-neoplastic gastric tis

26 g for FoxM1b in tumor cell nuclei in various gastric tumors and lymph node metastases.

27 ation Panel I assay on DNA extracted from 60 gastric tumors and matched tumor-adjacent gastric tissue

28 a plays a crucial role in the development of gastric tumors and polymorphisms in the IL-1 gene cluste

29 for tumor EBV status because only 7%-10% of gastric tumors and select NHL subtypes are related to EB

30 n, is highly expressed in intestinal subtype gastric tumors and that this signature associates with p

31 requency in different histologic subtypes of gastric tumors and these do not appear to be driver muta

32 at the intestinal lesion is secondary to the gastric tumor, and the mutation patterns in two cases in

33 cifically expressed in embryonic stem cells, gastric tumors, and hepatic stellate cells.

34 Intestinal and diffuse gastric tumors arise rapidly in this model that displays

35 e of RUNX3 protein expression in 86 cases of gastric tumors as compared with that in normal gastric m

36 re found in both intestinal and diffuse type gastric tumors as well as in tumors that exhibit both in

37 agnostically challenging case of cryptogenic gastric tumor associated with mesenteric panniculitis in

38 Here, we report a rare case of an occult gastric tumor associated with mesenteric panniculitis th

39 Gastric tumors become increasingly prevalent with advanc

40 cDNA, derived from primary gastric tumors before chemotherapy, was used to determin

41 Because fibrin is abundant in gastric tumors but not in healthy tissues, we hypothesiz

42 t reversal of homing receptor profile in the gastric tumor by antigen specific stimulation may be res

43 Gastric tumors can become resistant to gefitinib, an inh

44 Gastric tumors can bypass niche dependence by acquiring

45 In a gastric tumor cell line, neuronostatin induced c-Fos exp

46 Levels of CITED2 in gastric tumors correlate with patients' response to epir

47 Gastric tumors developed in 29% of 80-week-old Villin-Cr

48 cancer is not a common event during sporadic gastric tumor development, at least in patients from Nor

49 In total, 15 of 18 gastric tumors exhibited at least fivefold higher C/EBPb

50 Patients with ovarian or gastric tumors expressing higher levels of HtrA1 showed

51 ibiting Helicobacter infections and blocking gastric tumor formation offer hope that these mechanisms

52 ffects and requires MYC activation to induce gastric tumor formation.

53 ls and in mice subcutaneously implanted with gastric tumors formed by MKN1(DCLK1) cells.

54 cell lines and tumor samples, as well as in gastric tumors from CEA/Tag mice, compared with non-neop

55 The gastric tumors from the CIN mice had an invasive phenoty

56 The gastric tumors from the GS-TGFB mice were poorly differe

57 und that miR-135b-5p is also up-regulated in gastric tumors from the trefoil factor 1-knockout mouse

58 ssion of human gastrokines (GKNs) attenuated gastric tumor growth in gp130F/F mice.

59 Mouse and human gastric tumors had reduced expression of Kruppel-like fa

60 About 5% to 10% of human gastric tumors harbor oncogenic mutations in the KRAS pa

61 Because gastric tumors have been shown to contain a high percent

62 A significant proportion of gastric tumors have defects in the DNA damage response p

63 The multiplicity of gastric tumor in carcinogen-treated mice was significant

64 also maintain a high index of suspicion for gastric tumors in older patients who may present with at

65 ic progenitor cells (VGPCs) as the origin of gastric tumors in PPARD mice.

66 ells in mice and reversed the development of gastric tumors in Tff1(-/-) mice.

67 revealed loss of TFF1 expression in 56 of 59 gastric tumors in which 54 of these tumors exhibited ove

68 COX-2 expression (IHC) in gastric tumors inversely correlated with COX-2 gene meth

69 the cellular distribution of HER2 protein in gastric tumors is dynamic, and HER2 internalization decr

70 rstly constructed a carcinogen-induced mouse gastric tumor model combined with H. pylori infection an

71 Similar results with animal gastric tumor models were obtained in vivo.

72 In a mouse model of gastric tumors (N87), 40 stops tumor growth at 5 mg/kg a

73 Apc(Min/+);Foxl1-/- mice also develop gastric tumors not observed in Apc(Min) mice.

74 The volume of gastric tumors noticeably decreased during the course of

75 h the expression of NPM1 is heterogeneous in gastric tumors, our results suggest that NPM1 down-regul

76 aining showed strong PTGR2 expression in the gastric tumor portion, relative to nearby nontumor porti

77 he inhibition of the Kras gene expression in gastric tumors prevents the occurrence of metastasis to

78 astric carcinogenesis and increased rates of gastric tumor progression than control mice.

79 cell proliferation and migration leading to gastric tumor progression.

80 k of atrophic gastritis, and is considered a gastric tumor promoter.

81 We investigated the role of DARPP-32 in gastric tumor resistance to gefitinib.

82 and TP53 was observed in 45.5% and 21.2% of gastric tumors, respectively.

83 found in intron 8 of the TDG locus to screen gastric tumor samples for loss of heterozygosity.

84 We analyzed gastric tumor samples from patients using immunohistoche

85 Levels of CITED2 were increased in gastric tumor samples from patients who had complete res

86 ively correlated with those of VEGF in human gastric tumor samples.

87 MYC amplification was observed in 51.5% of gastric tumor samples.

88 showed significant CD44v8-10 upregulation in gastric tumor sites.

89 Findings were compared with those from human gastric tumor specimens.

90 with increased C/EBPbeta was observed in the gastric tumors studied.

91 Kruppel-like factor 4 (Klf4) is a putative gastric tumor suppressor gene.

92 he G(1) to S-phase cell cycle transition and gastric tumor suppressor gene.

93 using a custom library targeting 49 putative gastric tumor suppressor genes, as well as a "cancer gen

94 how that H. pylori infection inactivates the gastric tumor suppressor RUNX3 in a CagA-dependent manne

95 s an oncoprotein by blocking the activity of gastric tumor suppressor RUNX3.

96 TFF1 is a gastric tumor suppressor that protects gastric epithelia

97 Trefoil factor family-1 (TFF1) is a key gastric tumor-suppressor gene.

98 erform in vivo CRISPR knockout screening for gastric tumor suppressors using gastric murine organoids

99 Synchronous gastric tumors that consist of both gastrointestinal str

100 aled overexpression of C/EBPbeta in 10 of 13 gastric tumors that exhibited low expression of TFF1 at

101 Resected gastric tumor tissues (n = 102) were analyzed for p-Erk

102 evels were also significantly upregulated in gastric tumor tissues, when compared with paired nontumo

103 o occur at significantly higher frequency in gastric tumor tissues.

104 compared gene expression patterns among 248 gastric tumors; using a robust method of unsupervised cl

105 The neoplastic B cells in the gastric tumor were alpha 4 beta 7-, CD62L+, whereas the

106 ulated in a number of primary colorectal and gastric tumors when compared with matching normal tissue

107 utetium-177, to deliver radiation locally to gastric tumors with minimal toxicity.